Press Releases Year None2020201920182017 December 15, 2020 Lilly Announces Agreement to Acquire Prevail Therapeutics December 11, 2020 Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations November 30, 2020 Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia November 18, 2020 Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001 November 13, 2020 Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights November 10, 2020 Prevail Therapeutics to Present at Upcoming Investor Conferences November 2, 2020 Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO October 27, 2020 Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher Disease September 25, 2020 Prevail Therapeutics to Present at Upcoming Investor Conferences September 18, 2020 Prevail Therapeutics to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last » Displaying 1 - 10 of 32
